CN1714819A - Medicinal composition for treating coronary heart disease - Google Patents
Medicinal composition for treating coronary heart disease Download PDFInfo
- Publication number
- CN1714819A CN1714819A CN 200410019827 CN200410019827A CN1714819A CN 1714819 A CN1714819 A CN 1714819A CN 200410019827 CN200410019827 CN 200410019827 CN 200410019827 A CN200410019827 A CN 200410019827A CN 1714819 A CN1714819 A CN 1714819A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- borneolum syntheticum
- amount
- salviae miltiorrhizae
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 7
- 239000000203 mixture Substances 0.000 title claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 80
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 32
- 238000000605 extraction Methods 0.000 claims abstract description 29
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 26
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 12
- 239000003513 alkali Substances 0.000 claims abstract description 7
- 239000000706 filtrate Substances 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- 239000006187 pill Substances 0.000 claims description 31
- 239000000047 product Substances 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 18
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 239000012567 medical material Substances 0.000 claims description 14
- 229940057995 liquid paraffin Drugs 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 10
- 238000004064 recycling Methods 0.000 claims description 10
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 102000011759 adducin Human genes 0.000 claims description 3
- 108010076723 adducin Proteins 0.000 claims description 3
- 238000010411 cooking Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 239000002994 raw material Substances 0.000 claims 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 10
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 238000001914 filtration Methods 0.000 description 21
- -1 nitrous acid ester Chemical class 0.000 description 9
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 8
- 244000131316 Panax pseudoginseng Species 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 8
- 238000010298 pulverizing process Methods 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000006837 decompression Effects 0.000 description 7
- 239000004744 fabric Substances 0.000 description 7
- 239000002932 luster Substances 0.000 description 7
- 239000002304 perfume Substances 0.000 description 7
- 235000013599 spices Nutrition 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003680 myocardial damage Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to coronary heart disease treating medicine composition, and is especially one kind of medicine composition prepared with Chinese herbal medicine material and through special extraction process and other technological process. Specifically, the medicine composition is prepared with notoginseng, red sage and borneol, and through alkali extraction, concentration, alcohol precipitation, and adding supplementary material.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of coronary heart disease, refer to that especially a kind of is the pharmaceutical composition that the special extracting method of prepared using is made through special process with the Chinese herbal medicine.
Background technology
Along with the rejuvenation of growth in the living standard, world population aging and morbidity colony, cardiovascular and cerebrovascular vessel patient increases year by year, has become the second largest disease of harm humans health.Angina pectoris is a kind of caused by the temporary transient ischemia of cardiac muscle, anoxia, serves as the clinical syndrome of main performance with ictal chest pain or chest discomfort.Angina pectoris is meant because coronary atherosclerosis or spasm cause myocardial ischemia, the caused angina pectoris of anoxia, accounts for 90% of patient with angina pectoris.
The anginal method of treatment is based on blood vessel dilating, reduction blood viscosity, antiplatelet aggregation, anticoagulation at present.Traditional Western medicine of using is nitrate, nitrous acid ester, beta-receptor resistance preparation, calcium antagonist etc., but all has bigger toxic and side effects, should not take for a long time, mostly is symptomatic treatment and course of disease progress is not had bigger effect.For example take and occur jumping pain, palpitating speed in feeling of fullness in the head, the head behind the nitroglycerin sometimes, even faint and [, find again in recent years to cause severe hypotension [referring to contemporary Chinese medical journal 1997 referring to new pharmacology [the 14th edition) 264 page]; 7 (4): 42; Shaanxi medical journal 1996; 25 (5): 315], easily produce toleration [referring to southern nursing magazine 1996; 3 (5): 7-9] etc. problem has hindered its application clinically.
Though the anginal Chinese patent medicine of many treatments is also arranged, wherein ball, loose, cream, pellet, decoction becomes old historical already, the modern seldom uses.There are preparations such as common compound Salviae Miltiorrhizae tablet and capsule to sell in the market, but conventional tablet, capsule manufacture technology are more backward, active constituent content is low, no quality control standard, need be oral through gastrointestinal absorption, go into blood at liver generation first pass effect post-absorption, bioavailability is low, absorb slowly, can not be fit to the need of angina pectoris patient's first aid.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition with efficient, quick-acting, long lasting treatment coronary heart disease.
Another object of the present invention has provided the pharmacological action of aforementioned pharmaceutical compositions.
The present invention is implemented by following scheme:
Get Radix Salviae Miltiorrhizae, Radix Notoginseng and the Borneolum Syntheticum medical material of pulverizing; With Radix Salviae Miltiorrhizae and pseudo-ginseng and an amount of alkali, extracting in water filters, merging filtrate, and filtrate is suitably concentrated; Add ethanol and carry out precipitate with ethanol in concentrated solution, leave standstill, supernatant reclaims ethanol, is condensed into extractum; With gained extractum and Borneolum Syntheticum and adjuvant mixed evenly after, make preparation.
Concrete steps are as follows:
1. get a certain amount of Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneolum Syntheticum, standby;
2. will add an amount of alkali in above-mentioned Radix Salviae Miltiorrhizae, the Radix Notoginseng, heating extraction 2～4 times, each amount of water is 4～8 times of medical material amount, leach cooking liquid filters, merging filtrate, it is 1.10～1.30 (80 ± 5 ℃) that filtrate is concentrated into relative density;
3. add 95% ethanol in above-mentioned steps 2 described concentrated solutions, making determining alcohol is 50～85%, leaves standstill 4～24 hours, and supernatant filters, filtrate recycling ethanol, and the simmer down to relative density is the extractum of 1.15～1.45 (55～60 ℃);
With gained extractum and aforementioned proportion Borneolum Syntheticum and adjuvant mixed evenly after, make preparation.
Wherein, each medicine described in the step 1, its formulation ratio is (in a weight percentage):
Radix Salviae Miltiorrhizae 20%～97%, Radix Notoginseng 2%～80%, Borneolum Syntheticum 0.2%～3%;
Best proportioning is (in a weight percentage):
Radix Salviae Miltiorrhizae 82.87%, Radix Notoginseng 16.21%, Borneolum Syntheticum 0.92%;
The described alkali of step 2 is sodium carbonate, sodium bicarbonate, is preferably sodium bicarbonate, and addition is 1.0%～3.0% of a medical material amount, and is preferred 1.4%～1.9%, and the best is 1.81%; Extraction time is preferably 2 times, and for the first time amount of water is 4 times of medical material amount, extracts 2 hours, and the second time, amount of water was 3 times of medical material amount, extracted 1 hour; Filtrate is concentrated into relative density 1.20 (75 ± 1 ℃); Add the high concentration ethanol precipitation in the step 3, make to contain alcohol and reach 65%～70%, optium concentration is 68%; Be 8～12 hours quiescent time, and the best is 10 hours; Concentrating and reclaiming ethanol to relative density is 1.35～1.40 (55～60 ℃), and the best is 1.38 (55～60 ℃); Can make acceptable dosage form on any one pharmaceutics in the step 4, wherein preferred dosage form is a drop pill, and it is shaped as reddish brown-brownish black round bead shape, and size evenly.
The drop pill preparation method of medicine of the present invention be mainly with above-mentioned gained extractum and Borneolum Syntheticum and adjuvant mixed evenly after, add the transconversion into heat material, move into dripping jar of drop pill machine, medicine liquid droplet is removed liquid paraffin to cryogenic liquid paraffin, select ball.
Wherein: adjuvant is a Polyethylene Glycol-6000, and 53～58 ℃ of its condensation points, addition are extractum and Borneolum Syntheticum weight 2～6 times, and preferred 2～4 times, the best is 3 times; Changing the material temperature is 60～100 ℃, and optimum temperature is 85 ℃; The temperature of liquid paraffin is 0～10 ℃, and the best is 5～10 ℃; Ball heavily is 5～50mg/ grain, diameter 1.95～4.29mm.
The present invention utilizes modern special extraction process and high-tech Quality Control means, improves content of effective and quality control standard, really guarantees the safety and the effectiveness of medicine.Preferred dosage form drop pill of the present invention can be given full play to the dosage form advantage.Drop pill can be referred to as solid solution, and medicine is dispersed in the substrate with molecularity, forms uniform solid dispersion, and is can the bonding dosed administration accurate; Drug microparticles is embedded in the substrate, tight, and secluding air has increased stability of drug; After medicine and the substrate congruent melting medicine is dispersed in the substrate, condensation forms superfine crystallization, helps dissolving and absorbs, and brings into play curative effect rapidly, improves bioavailability, reduces side effect; Medicine is avoided first pass effect through sublingual administration, the bioavailability height; The effective ingredient oral transmucosal absorbs directly into blood, and the performance curative effect can reach quick-acting purposes.
Below by to the zooperal elaboration of invention drug regimen, the beneficial effect that it is used is described in pharmacy.
Protective effect to the Ischemia and Reperfusion in vivo in Rats myocardial damage
This research and inquirement pharmaceutical composition of the present invention is to the Ischemia and Reperfusion in vivo in Rats myocardial damage, the especially influence of apoptosis of cardiac muscle.
1. animal model: Wistar strain male rat, open chest anesthetized is kept breathing, around left coronary artery, and carries out ligation between left auricle and pulmonary conus.
2. method: rat is divided into 5 groups at random: 1. sham operated rats (sham-operated control), normal saline is irritated stomach, 1ml/ days, totally 4 days; 2. myocardial ischemia-reperfusion group (M-IR), it is the same to irritate the stomach method; 3. pharmaceutical composition I group of the present invention (DSPI) was dissolved in the 1ml normal saline with 150ml/kg/ days, irritated stomach (method is the same); 4. pharmaceutical composition II group of the present invention (DSPII), with 300ml/kg/ days, the same DSPI of all the other methods; 5. pharmaceutical composition III group of the present invention (DSPIII), with 450ml/kg/ days, the same DSPI of all the other methods.
Testing index:
2.1 myocardial infarct size is measured: ligation left coronary artery once more before the sacrifice of animal, take out after injecting 1% her Wen orchid in the ventricle, with the PBS rinsing, freezing 1h.After removing unnecessary tissue, the 30min that in 1%TTC, dyes (37 ℃).With weight method calculating myocardium ischemia hazardous area (she does not dye the district by the Wen orchid), infarcted region (TTC does not dye the district).
2.2 cardiomyocyte apoptosis cell in-situ marker detection and analysis: each heart get 3 different parts section each 1, press duPT breach end-labelling (TdT-mediateflourescein-duTP nick end labeling, TUNEL) DNA3 ' in the labelling cardiomyocyte apoptosis nucleus-OH end of the band fluorescence of end deoxyribonucleic acid transferase (TdT enzyme) mediation.Select 5 visuals field, in 300 myocardial cell of each visual field counting positive cell number with the shared percentage ratio of average computation positive cell number as the apoptosis of cardiac muscle positivity index (apoptotic index, AI)
3. result
3.1 the variation of myocardial infarct size: sham-operation 7h does not see the myocardial infarction phenomenon; Myocardial infarction was obvious after myocardial ischemia 1h poured into 6h again; Pharmaceutical composition of the present invention (DSP) can dwindle the ischemia-reperfusion myocardial infarct size, and increases with dosage, and myocardial infarct size dwindles and significantly sees Table 1.
Table 1 is respectively organized the variation of myocardial infarct size
| Group | Infarcted region weight/left ventricular mass (%) | Infarcted region weight/hazardous area weight (%) |
| The Sham-control group | 0 | 0 |
| The M-IR group | 41.8±7.9 | 63.2±8.6 |
| Pharmaceutical composition I group of the present invention | 34.6±7.2 **△ | 55.7±8.4 * |
| Pharmaceutical composition II group of the present invention | 27.1±6.5 **△ | 47.3±7.7 **△ |
| Pharmaceutical composition III group of the present invention | 19.4±6.1 **△△◇ | 38.9±7.5 **△△◇ |
Annotate: compare with the M-IR group,
*P＜0.05,
*P＜0.01; Compare with the I group,
△P＜0.05,
△ △P＜0.01; Compare with the II group,
◇P＜0.05.
3.2 the change of cardiomyocyte apoptosis cell: relatively large DSP can obviously reduce ischemia-reperfusion cardiac cellular apoptosis quantity, and AI descends along with the increase of DSP dosage, sees Table 2.2.
Table 2 is respectively organized the variation of apoptosis of cardiac muscle cell quantity
| Group | The example number | Myocardial cell AI (%) |
| The Sham-control group | 10 | 0.82±0.47 |
| The M-IR group | 10 | 22.76±13.17 |
| Pharmaceutical composition I group of the present invention | 10 | 20.93±13.25 * |
| Pharmaceutical composition II group of the present invention | 10 | 16.28±11.96 *△◇ |
Annotate: compare with the Sham-control group,
*P＜0.01; Compare with the M-IR group,
△P＜0.05,
△ △P＜0.01; Compare with the I group, P＜0.05,
◇ ◇P＜0.01; Compare with the II group,
▲P＜0.05
Conclusion: studies show that originally pharmaceutical composition of the present invention can obviously dwindle the myocardial infarct size of myocardial reperfusion rat, show that further pharmaceutical composition of the present invention pours into the myocardium cell necrosis variation again to ischemic myocardial cells good protective action is arranged.
The specific embodiment
The embodiment that enumerates the preparation aspect below further describes the present invention, and this embodiment only is used to the present invention is described and the present invention is not limited.
Embodiment 1
1. prescription consumption
Radix Salviae Miltiorrhizae 41.06g Radix Notoginseng 8.03g Borneolum Syntheticum 0.46g
Adjuvant Polyethylene Glycol-6000 18g
Make 1000 drop pill
2. the extraction of Radix Salviae Miltiorrhizae, Radix Notoginseng
Learn from else's experience the Radix Salviae Miltiorrhizae, pseudo-ginseng of coarse pulverization to extraction pot, add the 0.89g sodium bicarbonate, add 4 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 4 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into relative density 1.20 (75 ± 1 ℃), slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 68%, leaves standstill 10 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol, the simmer down to relative density is the extractum of 1.38 (55～60 ℃).
3. the preparation of product
Get above-mentioned extractum and Borneolum Syntheticum, evenly be heated to 85 ℃ of temperature, change material after 20～120 minutes, move in the dropping-pill machine jar that jar temperature remains on 85～90 ℃ with Polyethylene Glycol-6000 18g is mixed.In ℃ liquid paraffin of medicine liquid droplet to 7～8, take out drop pill, oil removing, screen cloth selects ball, promptly.
1. the feature of product
The product character is reddish brown-brownish black round bead shape, and size is even, color and luster is consistent, gas perfume (or spice), bitter in the mouth.
The product ball heavily is 25mg ± 15%/grain, diameter 3.34 ± 15%mm.
Embodiment 2
1. prescription consumption
Radix Salviae Miltiorrhizae 31.12g Radix Notoginseng 9.21g Borneolum Syntheticum 0.50g
Adjuvant Polyethylene Glycol-6000 20g
Make 1000 drop pill
2. the extraction of Radix Salviae Miltiorrhizae, Radix Notoginseng
Learn from else's experience the Radix Salviae Miltiorrhizae, pseudo-ginseng of coarse pulverization to extraction pot, add the 0.40g sodium bicarbonate, add 2 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 8 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into relative density 1.10 (75 ± 1 ℃), slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 50%, leaves standstill 8 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol, the simmer down to relative density is the extractum of 1.35 (55～60 ℃).
3. the preparation of product
Get above-mentioned extractum and Borneolum Syntheticum, evenly be heated to 60 ℃ of temperature, change material after 20～120 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃ with Polyethylene Glycol-6000 20g is mixed.In ℃ liquid paraffin of medicine liquid droplet to 7～8, take out drop pill, oil removing, screen cloth selects ball, promptly.
4. the feature of product
The product character is reddish brown-brownish black round bead shape, and size is even, color and luster is consistent, gas perfume (or spice), bitter in the mouth.The product ball heavily is 25mg ± 15%/grain, diameter 3.34 ± 15%mm.
Embodiment 3
1. prescription consumption
Radix Salviae Miltiorrhizae 31.12g Radix Notoginseng 9.21g Borneolum Syntheticum 0.50g
Adjuvant Polyethylene Glycol-6000 20g
Make 1000 drop pill
2. the extraction of Radix Salviae Miltiorrhizae, Radix Notoginseng
Learn from else's experience the Radix Salviae Miltiorrhizae, pseudo-ginseng of coarse pulverization to extraction pot, add the 0.40g sodium carbonate, add 2 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 8 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into relative density 1.10 (75 ± 1 ℃), slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 50%, leaves standstill 8 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol, the simmer down to relative density is the extractum of 1.35 (55～60 ℃).
3. the preparation of product
Get above-mentioned extractum and Borneolum Syntheticum, evenly be heated to 60 ℃ of temperature, change material after 20～120 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃ with Polyethylene Glycol-6000 20g is mixed.In ℃ liquid paraffin of medicine liquid droplet to 7～8, take out drop pill, oil removing, screen cloth selects ball, promptly.
4. the feature of product
The product character is reddish brown-brownish black round bead shape, and size is even, color and luster is consistent, gas perfume (or spice), bitter in the mouth.The product ball heavily is 25mg ± 15%/grain, diameter 3.34 ± 15%mm.
Embodiment 4
1. prescription consumption
Radix Salviae Miltiorrhizae 59.36g Radix Notoginseng 6.38g Borneolum Syntheticum 0.34g
Adjuvant Polyethylene Glycol-6000 21g
Make 1000 drop pill
2. the extraction of Radix Salviae Miltiorrhizae, Radix Notoginseng
Learn from else's experience the Radix Salviae Miltiorrhizae, pseudo-ginseng of coarse pulverization to extraction pot, add the 1.97g sodium bicarbonate, add 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 5 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into relative density 1.10 (75 ± 1 ℃), slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 85%, leaves standstill 8 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol, the simmer down to relative density is the extractum of 1.40 (55～60 ℃).
3. the preparation of product
Get above-mentioned extractum and Borneolum Syntheticum, evenly be heated to 100 ℃ of temperature, change material after 20～120 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃ with Polyethylene Glycol-6000 20g is mixed.In ℃ liquid paraffin of medicine liquid droplet to 7～8, take out drop pill, oil removing, screen cloth selects ball, promptly.
4. the feature of product
The product character is reddish brown-brownish black round bead shape, and size is even, color and luster is consistent, gas perfume (or spice), bitter in the mouth.The product ball heavily is 25mg ± 15%/grain, diameter 3.34 ± 15%mm.
Embodiment 5
1. prescription consumption
Radix Salviae Miltiorrhizae 59.36g Radix Notoginseng 6.38g Borneolum Syntheticum 0.34g
Adjuvant Polyethylene Glycol-6000 21g
Make 1000 drop pill
2. the extraction of Radix Salviae Miltiorrhizae, Radix Notoginseng
Learn from else's experience the Radix Salviae Miltiorrhizae, pseudo-ginseng of coarse pulverization to extraction pot, add the 1.97g sodium carbonate, add 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 5 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into relative density 1.10 (75 ± 1 ℃), slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 85%, leaves standstill 8 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol, the simmer down to relative density is the extractum of 1.40 (55～60 ℃).
3. the preparation of product
Get above-mentioned extractum and Borneolum Syntheticum, evenly be heated to 100 ℃ of temperature, change material after 20～120 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃ with Polyethylene Glycol-6000 20g is mixed.In ℃ liquid paraffin of medicine liquid droplet to 7～8, take out drop pill, oil removing, screen cloth selects ball, promptly.
4. the feature of product
The product character is reddish brown-brownish black round bead shape, and size is even, color and luster is consistent, gas perfume (or spice), bitter in the mouth.The product ball heavily is 25mg ± 15%/grain, diameter 3.34 ± 15%mm.
Embodiment 6
1. prescription consumption
Radix Salviae Miltiorrhizae 10g Radix Notoginseng 38.5g Borneolum Syntheticum 1.5g
Adjuvant Polyethylene Glycol-6000 18g
Make 1000 drop pill
2. the extraction of Radix Salviae Miltiorrhizae, Radix Notoginseng
Learn from else's experience the Radix Salviae Miltiorrhizae, pseudo-ginseng of coarse pulverization to extraction pot, add the 0.89g sodium bicarbonate, add 4 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 4 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into relative density 1.20 (75 ± 1 ℃), slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 68%, leaves standstill 10 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol, the simmer down to relative density is the extractum of 1.38 (55～60 ℃).
3. the preparation of product
Get above-mentioned extractum and Borneolum Syntheticum, evenly be heated to 85 ℃ of temperature, change material after 20～120 minutes, move in the dropping-pill machine jar that jar temperature remains on 85～90 ℃ with Polyethylene Glycol-6000 18g is mixed.In ℃ liquid paraffin of medicine liquid droplet to 7～8, take out drop pill, oil removing, screen cloth selects ball, promptly.
4. the feature of product
The product character is reddish brown-brownish black round bead shape, and size is even, color and luster is consistent, gas perfume (or spice), bitter in the mouth.
The product ball heavily is 25mg ± 15%/grain, diameter 3.34415%mm.
Embodiment 7
1. prescription consumption
Radix Salviae Miltiorrhizae 15g Radix Notoginseng 34g Borneolum Syntheticum 1g
Adjuvant Polyethylene Glycol-6000 18g
Make 1000 drop pill
2. the extraction of Radix Salviae Miltiorrhizae, Radix Notoginseng
Learn from else's experience the Radix Salviae Miltiorrhizae, pseudo-ginseng of coarse pulverization to extraction pot, add the 0.89g sodium bicarbonate, add 4 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 4 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into relative density 1.20 (75 ± 1 ℃), slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 68%, leaves standstill 10 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol, the simmer down to relative density is the extractum of 1.38 (55～60 ℃).
3. the preparation of product
Get above-mentioned extractum and Borneolum Syntheticum, evenly be heated to 85 ℃ of temperature, change material after 20～120 minutes, move in the dropping-pill machine jar that jar temperature remains on 85～90 ℃ with Polyethylene Glycol-6000 18g is mixed.In ℃ liquid paraffin of medicine liquid droplet to 7～8, take out drop pill, oil removing, screen cloth selects ball, promptly.
4. the feature of product
The product character is reddish brown-brownish black round bead shape, and size is even, color and luster is consistent, gas perfume (or spice), bitter in the mouth.
The product ball heavily is 25mg ± 15%/grain, diameter 3.34 ± 15%mm.
Claims (15)
1. pharmaceutical composition for the treatment of coronary heart disease is characterized in that adopting following step to make:
1. get a certain amount of Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneolum Syntheticum, standby;
2. will add an amount of alkali in above-mentioned Radix Salviae Miltiorrhizae, the Radix Notoginseng, heating extraction 2～4 times, each amount of water is 4～8 times of medical material amount, leach cooking liquid filters, merging filtrate, it is 1.10～1.30 (80 ± 5 ℃) that filtrate is concentrated into relative density;
3. add 95% ethanol in above-mentioned steps 2 described concentrated solutions, making determining alcohol is 50～85%, leaves standstill 4～24 hours, and supernatant filters, filtrate recycling ethanol, and the simmer down to relative density is the extractum of 1.15～1.45 (55～60 ℃);
With gained extractum and aforementioned proportion Borneolum Syntheticum and adjuvant mixed evenly after, make preparation.
2. according to the described pharmaceutical composition of claim 1, it is characterized in that the weight proportion of each raw material is in the step 1:
Radix Salviae Miltiorrhizae 20%～97%, Radix Notoginseng 2%～80%, Borneolum Syntheticum 0.2%～3%.
3. according to claim 1 or 2 described pharmaceutical compositions, it is characterized in that the weight proportion of each raw material is:
Radix Salviae Miltiorrhizae 82.87%, Radix Notoginseng 16.21%, Borneolum Syntheticum 0.92%.
4. pharmaceutical composition according to claim 1 is characterized in that the described alkali of step 2 is selected from sodium carbonate or sodium bicarbonate, and addition is 1.0%～3.0% of a medical material amount.
5. according to claim 1 or 4 described pharmaceutical compositions, it is characterized in that described alkali is sodium bicarbonate, addition is 1.81% of a medical material amount.
6. pharmaceutical composition according to claim 1, it is characterized in that the extraction time described in the step 2 is 2 times, for the first time the frame water yield is 4 times of medical material amount, and amount of water is 3 times of medical material amount for the second time, and filtrate concentrating is meant and is concentrated into relative density 1.20 (75 ± 1 ℃).
7. pharmaceutical composition according to claim 1 is characterized in that alcoholic acid addition described in the step 3 is to make the determining alcohol of precipitate with ethanol solution reach 50～85%.
8. according to claim 1 or 7 described pharmaceutical compositions, it is characterized in that described alcoholic acid addition is to make the determining alcohol of precipitate with ethanol solution reach 68%.
9. pharmaceutical composition according to claim 1 is characterized in that time of repose described in the step 2 is 10 hours, and the relative density of concentrated extract is 1.38 (55～60 ℃).
10. pharmaceutical composition according to claim 1 is characterized in that preparation described in the step 4 can be a said dosage form on any pharmaceutics.
11. pharmaceutical composition according to claim 10 is characterized in that preferred dosage form is a drop pill.
12. according to claim 1 or 11 described pharmaceutical compositions, the preparation method that it is characterized in that described drop pill is for after mixing gained extractum and Borneolum Syntheticum and adjuvant in claim 1 step 3 evenly, add the transconversion into heat material, move into the dropping-pill machine jar, medicine liquid droplet is to cryogenic liquid paraffin, remove liquid paraffin, select ball.
13. pharmaceutical composition according to claim 12 is characterized in that described adjuvant is a Polyethylene Glycol-6000, addition is extractum and Borneolum Syntheticum weight 2～6 times.
14. pharmaceutical composition according to claim 13, the addition that it is characterized in that described adjuvant Polyethylene Glycol-6000 are extractum and Borneolum Syntheticum weight 3 times.
15. pharmaceutical composition according to claim 1 is characterized in that described step is as follows:
1. get weight proportion and be the medical material of Radix Salviae Miltiorrhizae 82.87%, Radix Notoginseng 16.21%, Borneolum Syntheticum 0.92%, standby;
2. an amount of sodium bicarbonate will be added in above-mentioned Radix Salviae Miltiorrhizae, the Radix Notoginseng, addition is 1.81% of a medical material amount, heating extraction 2 times, for the first time the frame water yield is 4 times of medical material amount, extracts 2 hours, and the second time, amount of water was 3 times of medical material amount, extracted 1 hour, leach cooking liquid filters, merging filtrate, and it is 1.20 (75 ± 1 ℃) that filtrate is concentrated into relative density;
3. add 95% ethanol in above-mentioned steps 3 described concentrated solutions, making determining alcohol is 68%, leaves standstill 10 hours, and supernatant filters, filtrate recycling ethanol, and the simmer down to relative density is the extractum of 1.38 (55～60 ℃);
With gained extractum and aforementioned proportion Borneolum Syntheticum and adjuvant mixed evenly after, add Polyethylene Glycol-6000, mix homogeneously is heated to 85 ℃, changes material, moves in the drop pill machine, in the liquid paraffin of medicine liquid droplet to 7～8 ℃, takes out drop pill, oil removing obtains product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100198273A CN100404041C (en) | 2004-06-30 | 2004-06-30 | Medicinal composition for treating coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100198273A CN100404041C (en) | 2004-06-30 | 2004-06-30 | Medicinal composition for treating coronary heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1714819A true CN1714819A (en) | 2006-01-04 |
| CN100404041C CN100404041C (en) | 2008-07-23 |
Family
ID=35821179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100198273A Expired - Lifetime CN100404041C (en) | 2004-06-30 | 2004-06-30 | Medicinal composition for treating coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100404041C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102028746A (en) * | 2009-09-29 | 2011-04-27 | 天津天士力现代中药资源有限公司 | Drug for treating coronary heart disease and extraction method |
| CN102028743A (en) * | 2009-09-29 | 2011-04-27 | 天津天士力现代中药资源有限公司 | Medicament for treating coronary heart disease and preparation method thereof |
| CN102028740A (en) * | 2009-09-29 | 2011-04-27 | 天津天士力现代中药资源有限公司 | Medicament for treating coronary heart disease and preparation process thereof |
| CN103068398A (en) * | 2010-08-06 | 2013-04-24 | 天士力制药集团股份有限公司 | Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease |
| CN104274518A (en) * | 2013-07-11 | 2015-01-14 | 天士力制药集团股份有限公司 | Traditional Chinese medicine (TCM) composition and preparation |
| CN104274520A (en) * | 2013-07-11 | 2015-01-14 | 天士力制药集团股份有限公司 | Traditional Chinese medicine (TCM) composition and preparation thereof |
| US10626077B2 (en) | 2013-08-29 | 2020-04-21 | Tasly Pharmaceutical Group Co., Ltd. | Salvianolic acid compound T, preparation method therefor, and use thereof |
| US11013694B2 (en) | 2013-07-11 | 2021-05-25 | Tasly Pharmaceutical Group Co., Ltd. | Formulation of a micro drop pill and the preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1069540C (en) * | 1999-08-11 | 2001-08-15 | 河北省药品检验所 | preparation process of compound red sage tablet |
-
2004
- 2004-06-30 CN CNB2004100198273A patent/CN100404041C/en not_active Expired - Lifetime
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102028746A (en) * | 2009-09-29 | 2011-04-27 | 天津天士力现代中药资源有限公司 | Drug for treating coronary heart disease and extraction method |
| CN102028743A (en) * | 2009-09-29 | 2011-04-27 | 天津天士力现代中药资源有限公司 | Medicament for treating coronary heart disease and preparation method thereof |
| CN102028740A (en) * | 2009-09-29 | 2011-04-27 | 天津天士力现代中药资源有限公司 | Medicament for treating coronary heart disease and preparation process thereof |
| CN102028743B (en) * | 2009-09-29 | 2014-12-24 | 天津天士力现代中药资源有限公司 | Medicament for treating coronary heart disease and preparation method thereof |
| CN102028746B (en) * | 2009-09-29 | 2014-12-24 | 天津天士力现代中药资源有限公司 | Drug for treating coronary heart disease and extraction method |
| CN103068398A (en) * | 2010-08-06 | 2013-04-24 | 天士力制药集团股份有限公司 | Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease |
| CN103068398B (en) * | 2010-08-06 | 2015-08-19 | 天士力制药集团股份有限公司 | Red sage root composition is for the preparation of the purposes in the medicine of Coronary heart disease |
| WO2015003659A1 (en) * | 2013-07-11 | 2015-01-15 | 天士力制药集团股份有限公司 | Traditional chinese medicine composition, and preparation and application thereof |
| CN104274520A (en) * | 2013-07-11 | 2015-01-14 | 天士力制药集团股份有限公司 | Traditional Chinese medicine (TCM) composition and preparation thereof |
| CN104274518A (en) * | 2013-07-11 | 2015-01-14 | 天士力制药集团股份有限公司 | Traditional Chinese medicine (TCM) composition and preparation |
| CN104274520B (en) * | 2013-07-11 | 2018-04-27 | 天士力医药集团股份有限公司 | A kind of Chinese medicine composition and its preparation |
| US9999630B2 (en) | 2013-07-11 | 2018-06-19 | Tasly Pharmaceutical Group Co., Ltd. | Traditional chinese medicine composition, and preparation and application thereof |
| CN104274518B (en) * | 2013-07-11 | 2018-08-03 | 天士力医药集团股份有限公司 | A kind of Chinese medicine composition and preparation |
| EA034217B1 (en) * | 2013-07-11 | 2020-01-17 | Тасли Фармасьютикал Груп Ко., Лтд. | Traditional chinese medicine composition, pharmaceutical preparation and micro drop pill thereof, preparation method for the micro drop pill and use of the composition |
| US11013694B2 (en) | 2013-07-11 | 2021-05-25 | Tasly Pharmaceutical Group Co., Ltd. | Formulation of a micro drop pill and the preparation method thereof |
| USRE49035E1 (en) | 2013-07-11 | 2022-04-19 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
| USRE49050E1 (en) | 2013-07-11 | 2022-04-26 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
| US10626077B2 (en) | 2013-08-29 | 2020-04-21 | Tasly Pharmaceutical Group Co., Ltd. | Salvianolic acid compound T, preparation method therefor, and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100404041C (en) | 2008-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN1714819A (en) | Medicinal composition for treating coronary heart disease | |
| CN1686439A (en) | Kelu drip pill used for phlegm transforming cough suppressing and its preparation method | |
| CN1698851A (en) | Stomach nourishing dispersible tablet with aucklandia root and amomum fruit and its preparation method | |
| CN1316964C (en) | Cough asthma stoppig drip pill and its preparation method | |
| CN1316960C (en) | Compound mactra clam drip pill and its preparation method | |
| CN1686484A (en) | Bastard feverfew throat clearing drip pill and its preparation method | |
| CN1316961C (en) | Grosvenor's momordica fruit drip pill an dits preparation method | |
| CN1682819A (en) | Sihuang intense heat purging dripping pill and its preparing method | |
| CN1626143A (en) | Medication for treating pharyngitis | |
| CN1301099C (en) | Earthworm drip pill and its preparation method | |
| CN1686479A (en) | Loquat drip pill for treating cough and its preparation method | |
| CN1297254C (en) | Drop pills containing bear gall and tendril-leaved fritillary bulb and preparation method thereof | |
| CN1626124A (en) | Drop pills of medical broth of small bupleurum root | |
| CN1284529C (en) | Compound gastrodia elata drop pills | |
| CN1634478A (en) | Tendril-leaved fritillary bulb loquat drop pills and preparation method thereof | |
| CN1682821A (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN1872250A (en) | Composition of medication for treating headache | |
| CN1682920A (en) | Anshenning dripping pill for treating neurosism and its preparing method | |
| CN1686454A (en) | Xiaoke drip pill used for suppressing cough and transforming phlegm and its preparation method | |
| CN1294902C (en) | Cough and asthma relieving drop pills prepared using dahurian rhododendron leaf | |
| CN1723954A (en) | Dripping pills made from black-bone chicken, and its prepn. method | |
| CN1742937A (en) | Chinese medicine preparation for treating cardiovascular and cerebrovascular and preparing method | |
| CN1709411A (en) | liver-clearing dropping pill for treating hepatitis and its preparing method | |
| CN1307978C (en) | Drop pill for diminishing inflammation in four seasons and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CX01 | Expiry of patent term |
Granted publication date: 20080723 |
|
| CX01 | Expiry of patent term |